{
  "id": 10117385,
  "title": "Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21",
  "url": "https://urgent.news/2026/09/27/grail-ceo-joshua-ofman-sells-6-0m-in-company-stock-on-sept-21",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T02:30:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/grail-ceo-joshua-ofman-sells-60m-in-company-stock-on-sept-21-93CH-4918722"
  },
  "original_language": "en",
  "account": "Joshua Ofman, CEO and Director of GRAIL, Inc. (NASDAQ:GRAL), sold a significant amount of company stock on September 21, 2026, totaling $6,006,378 worth of shares. The sales occurred under a Rule 10b5-1 trading plan he put in place on December 2, 2025. Following the sale, GRAIL’s stock price rose to $126.89, nearing its 52-week high. Despite the company’s market cap of $5.67 billion and ongoing losses, InvestingPro analysis indicates that GRAIL appears overvalued. In the same transaction, Ofman also bought 26,452 shares through stock options, exercising them at $14 per share, for a total cost of $370,328. As of the sale date, he owns 362,271 GRAIL shares directly and holds 37,032 derivative securities. GRAIL reported a revenue of $44.7 million in Q2, exceeding expectations, but reported a loss of $2.56 per share. The FDA has approved the Galleri test for early cancer detection, with a 10-0 vote for safety and a 6-4 vote for effectiveness. Analysts have mixed opinions on GRAIL's market performance, with Canaccord Genuity maintaining a Buy rating and Mizuho raising its price target.",
  "summary": null,
  "key_points": [
    "CEO Joshua Ofman sold $6.0m in GRAIL stock on September 21, 2026",
    "Sales under Rule 10b5-1 plan, stock rose to $126.89",
    "Ofman bought 26,452 shares through options for $370,328"
  ],
  "editors_take": "The CEO's stock sale, made under a pre-set trading plan, does not appear to have dented investor confidence, with GRAIL's stock price nearing its 52-week high afterwards.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "OnKure Therapeutics CFO Jason Leverone sells $898 in stock",
        "url": "https://urgent.news/2026/09/27/onkure-therapeutics-cfo-jason-leverone-sells-898-in-stock",
        "published": "2026-09-27T01:31:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}